Unlock Exclusive Discounts & Flash Sales! Click Here to Join the Deals on Every Wednesday!

In Vivo Pharmacodynamic Evaluation of Carbon Tetrachloride (CCl4) Induced Hepatic Fibrosis and Cirrhosis in Mouse Models (CAT#: STEM-AE-0666-LGZ)

Introduction

Metabolic diseases are diseases caused by the accumulation or deficiency of certain metabolic substances such as sugars, fats, proteins (amino acids), purines, pyrimidines, and copper when biochemical processes in the body are disrupted. Symptoms vary in severity and diagnosis depends on clinical manifestations and blood, urine and other biochemical tests. There is no effective cure, the main is to eliminate the cause and symptomatic treatment. The prognosis depends on the etiology, severity of symptoms and treatment effect.




Principle

Carbon tetrachloride (CCl4) induced liver fibrosis and cirrhosis in mice is a widely accepted experimental model for the study of liver fibrosis and cirrhosis. It reflects in many ways the pattern of human disease associated with toxic injury, such as α-SMA expression, stellate cell activation, and key matrix components including collagen-1, matrix metalloproteinases and their inhibitors TIMPs have been demonstrated in the pathogenesis of this model. The induction of CCl4 induces a reproducible and predictable fibrotic response in the liver, making it a valuable basis for preclinical pharmacological studies of anti-fibrosis and anti-cirrhosis therapies and for pathophysiological studies of fibrosis -- cirrhosis -- liver cancer changes.

Applications

Metabolic Disease

Procedure

1. Disease model construction.
2. Mice dosing.
3. Efficacy monitoring.
4. Biochemical detection of tissue samples.

Materials

• Sample Type: liquid or powder
Advertisement